Completed PHASE3 INTERVENTIONAL 2-arm NCT00945945

A Study of Duloxetine in Patients With Osteoarthritis Knee Pain

A Phase 3b Study to Assess the Efficacy of Duloxetine 60 mg Once Daily Compared With Placebo on the Reduction of Pain Caused by Osteoarthritis of the Knee, in a 13-week, Double-blind, Randomized Study

Sponsor: Eli Lilly and Company

Conditions Osteoarthritis Knee Pain

Interventions Duloxetine (DLX) Placebo (PLA)

Updated 8 times since 2017 Last updated: Feb 11, 2011 Started: Jul 31, 2009 Primary completion: May 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Osteoarthritis Knee Pain and is currently completed. Eli Lilly and Company leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Barcelona, Spain , Berlin, Germany , Bucharest, Romania , Clinton, United States , Getafe, Spain , Hamburg, Germany , Heraklion, Greece , Kifissia, Greece , Lake Jackson, United States and 16 more locations